Page last updated: 2024-10-21

2-amino-5-phosphonovalerate and Deafness

2-amino-5-phosphonovalerate has been researched along with Deafness in 1 studies

2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.

Deafness: A general term for the complete loss of the ability to hear from both ears.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hakuba, N1
Koga, K1
Shudou, M1
Watanabe, F1
Mitani, A1
Gyo, K1

Other Studies

1 other study available for 2-amino-5-phosphonovalerate and Deafness

ArticleYear
Hearing loss and glutamate efflux in the perilymph following transient hindbrain ischemia in gerbils.
    The Journal of comparative neurology, 2000, Mar-06, Volume: 418, Issue:2

    Topics: 2-Amino-5-phosphonovalerate; Animals; Audiometry, Evoked Response; Cerebrovascular Circulation; Coch

2000